Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Alopecia areata patients have lower zinc, copper, and selenium levels than healthy people.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

CD2 might be a new treatment target for patchy alopecia areata.

Higher IL-17A levels indicate more severe alopecia areata.

PPARα agonists may help treat alopecia areata by reducing inflammation.

Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

Various local treatments for alopecia areata show promise, but individualized plans and more research are needed.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Low vitamin D receptor levels found in hair loss patients; topical vitamin D treatment suggested.

Lipid–polymer hybrid nanoparticles can improve genome editing delivery and outcomes.

Increased HIF-1α is linked to the inflammation and severity of hidradenitis suppurativa, suggesting treatments that lower HIF-1α could help.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Platelets play a key role in the immune system and their lifespan and aging are important for developing new treatments.

Melatonin directly affects mouse hair follicles and may influence hair growth.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

The first Japanese family with Marie Unna hereditary hypotrichosis showed hair condition improvement in a child and highlighted the risk of misdiagnosis.

Changes in skin microbes play a role in some skin diseases and could lead to new treatments.

New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

Mothers with alopecia areata have a higher risk of adverse birth outcomes.

Vitamin D receptor interacts with certain dietary components to help prevent diseases and regulate hair growth.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.

Vitamins A, B3, C, D, and E can improve skin health and immunity.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.